Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012388 · ClinicalTrials.gov registry record · Phase 4
Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color
A Phase 4 study, sponsored by Merz North America.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT01012388 is a Phase 4 study that has completed, run by Merz North America. The registered enrollment target is 100 participants.
The verdict
NCT01012388, a Phase 4 study, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
Post marketing study to assess the likelihood of hypertropic scarring, keloid formation and hyper- or hypopigmentation in patients with Fitzpatrick Skin Types IV, V, and VI receiving nasolabial fold treatment with Radiesse® Injectable Dermal Filler
Interventions
- DEVICE Radiesse® Injectable Dermal Filler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01012388
The ClinicalTrials.gov registry entry for NCT01012388 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz North America, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiesse® Injectable Dermal Filler is the first listed.
NCT01012388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01012388 about?
NCT01012388 is a clinical study titled "Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds in Persons of Color". Post marketing study to assess the likelihood of hypertropic scarring, keloid formation and hyper- or hypopigmentation in patients with Fitzpatrick Skin Types IV, V, and VI receiving nasolabial fold treatment with Radiesse® Injectable Dermal Filler
What is the current status of trial NCT01012388?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2007-03. Estimated completion is 2008-02.
What interventions are being tested in trial NCT01012388?
The interventions under investigation include: Radiesse® Injectable Dermal Filler (DEVICE).
Who is sponsoring clinical trial NCT01012388?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.